Scilex Holding Company (SCLX) Financial Analysis & Valuation | Quarter Chart
Scilex Holding Company (SCLX)
SCLXPrice: $6.92
Fair Value: 🔒
🔒score
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with p... more
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-o... more
Description
Shares
| Market Cap | $58.77M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Henry H. Ji |
| IPO Date | 2021-03-05 | CAGR | 0.06% |
| Employees | 115 | Website | www.scilexholding.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SCLX chart loading...
Fundamentals
Technicals
| Enterprise Value | $213.39M | P/E Ratio | -0.2 |
| Forward P/E | 8.63 | PEG Ratio | — |
| P/S Ratio | 1.94 | P/B Ratio | -0.23 |
| P/CF Ratio | 14.28 | P/FCF Ratio | 17.16 |
| EPS | $-40.46 | EPS Growth 1Y | 73.64% |
| EPS Growth 3Y | 17790.14% | EPS Growth 5Y | 10247.39% |
| Revenue Growth 1Y | -46.54% | Gross Margin | 0.6% |
| Operating Margin | -9% | Profit Margin | -13.3% |
| ROE | 1.9% | ROA | -1.1% |
| ROCE | 2.3% | Current Ratio | 0.08 |
| Quick Ratio | 0.07 | Cash Ratio | 0.01 |
| Debt/Equity | -0.64 | Interest Coverage | -23.77 |
| Altman Z Score | -8.09 | Piotroski Score | 2 |